Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.25% | -45.75% | -320.94% | 88.46% | -356.88% |
| Total Depreciation and Amortization | 2.97% | -22.20% | 2.51% | -0.89% | 0.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.05% | 208.76% | -119.97% | 499.37% | -79.20% |
| Change in Net Operating Assets | -5.60% | 53.47% | 179.89% | -189.71% | 401.34% |
| Cash from Operations | -22.22% | 42.55% | 246.19% | -305.79% | 54.56% |
| Capital Expenditure | 8.48% | -- | -- | -269.38% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 17.06% | -- | -- | -269.38% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -1.85% | -2.86% | -1.94% | -1.98% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -143.75% | 38.46% | 49.02% | 36.25% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -44.07% | 34.00% | 7.70% | 21.52% | -221.28% |
| Foreign Exchange rate Adjustments | -531.03% | -3.33% | 134.09% | -153.66% | 175.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.94% | -450.23% | 123.17% | -205.96% | -318.63% |
